Scott Capps - CryoLife Vice President - Clinical Research
President
Mr. Scott B. Capps is Vice President Clinical Research of the Company. He served as Vice President, General Manager of CryoLife Europa, Ltd. in the U.K. from February 2005 to November 2007 and Director, European Clinical Affairs from April 2003 to January 2005. Mr. Capps joined CryoLife in 1995 as Project Engineer for the allograft heart valve program and was promoted to Director, Clinical Research in 1999. Mr. Capps is responsible for overseeing and implementing clinical trials to achieve FDA and International approval of CryoLifes medical products in cardiac, vascular, and orthopaedic clinical areas. Before joining CryoLife, Mr. Capps was a Research Assistant in the Department of Bioengineering at Clemson University working to develop a computerized database and radiographic image analysis system for total knee replacement since 2007.
| Age | 53 |
| Tenure | 17 years |
| Phone | 770 426-0031 |
| Web | www.Artivion.com |
CryoLife Management Efficiency
The company has Return on Asset of 1.01 % which means that on every $100 spent on assets, it made $1.01 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.57 %, implying that it generated $0.57 on every 100 dollars invested. CryoLife's management efficiency ratios could be used to measure how well CryoLife manages its routine affairs as well as how well it operates its assets and liabilities.CryoLife has 363.37 M in debt with debt to equity (D/E) ratio of 1.17, which is OK given its current industry classification. CryoLife has a current ratio of 4.13, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for CryoLife to invest in growth at high rates of return.
Similar Executives
| Found 11 records | PRESIDENT Age | ||
| Pipasu Soni | United States Steel | 45 | |
| James Bruno | United States Steel | 58 | |
| Douglas Matthews | United States Steel | 53 | |
| Sara Greenstein | United States Steel | 45 | |
| Timothy Go | HF Sinclair Corp | 57 | |
| Richard Voliva | HF Sinclair Corp | 42 | |
| Duane Holloway | United States Steel | 51 | |
| Christine Breves | United States Steel | 64 | |
| Scott Buckiso | United States Steel | 57 | |
| Richard Fruehauf | United States Steel | 53 | |
| Daniel Brown | United States Steel | 51 | |
Management Performance
| Return On Equity | 0.57 | |||
| Return On Asset | 1.01 |
CryoLife Leadership Team
Elected by the shareholders, the CryoLife's board of directors comprises two types of representatives: CryoLife inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CryoLife. The board's role is to monitor CryoLife's management team and ensure that shareholders' interests are well served. CryoLife's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CryoLife's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Mackin, Chairman of the Board, President, Chief Executive Officer, Director | ||
| Anthony Semedo, Independent Director | ||
| Daniel Bevevino, Independent Director | ||
| Dennis Maier, Vice President - Operations | ||
| Ronald McCall, Presiding Independent Director | ||
| Thomas Bogenschutz, Senior Vice President - EMEA, General Manager - Hechingen | ||
| Jeffrey Burbank, Independent Director | ||
| Jon Salveson, Independent Director | ||
| Jean Holloway, Senior Vice President, Chief Compliance Officer, General Counsel, Secretary | ||
| Thomas Ackerman, Independent Director | ||
| F Barthold, Vice President - Research and Development | ||
| Harvey Morgan, Independent Director | ||
| Amy Horton, Chief Accounting Officer, Vice President | ||
| Scott Capps, Vice President - Clinical Research | ||
| Marna Borgstrom, Independent Director | ||
| Michael Simpson, Senior Vice President - Regulatory Affairs and Quality Assurance | ||
| John Davis, Senior Vice President - Global Sales and Marketing | ||
| James Bullock, Independent Director | ||
| Matthew Getz, Vice President - Human Resources | ||
| D Lee, Chief Financial Officer, Chief Operating Officer, Executive Vice President |
CryoLife Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CryoLife a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.57 | |||
| Return On Asset | 1.01 | |||
| Profit Margin | 0.63 % | |||
| Operating Margin | 12.82 % | |||
| Current Valuation | 1.07 B | |||
| Shares Outstanding | 39.33 M | |||
| Shares Owned By Insiders | 3.70 % | |||
| Shares Owned By Institutions | 83.78 % | |||
| Number Of Shares Shorted | 3.47 M | |||
| Price To Earning | 425.71 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in CryoLife Stock
If you are still planning to invest in CryoLife check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CryoLife's history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |